Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genfit (NASDAQ: GNFT ) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (OTCMKTS: IPSEY ). Source: Shutterstock Let’s dive into that recent ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! Source: Shutterstock Moving stocks this morning is new analyst coverage, deals, earni...
Genfit (NASDAQ:GNFT) gains 8.5% after-hours after entering into an agreement with and Ipsen (OTCPK:IPSEF) under which, Ipsen will acquire exclusive worldwide license to develop, manufacture and commercialize Genfit's investigational treatment elafibranor, for people with P...
Agreement gives Ipsen global * rights to develop and commercialize GENFIT’s late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELAT...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021 Canada NewsWire NEW YORK , Nov. 11, 2021 /CNW/ - Deutsche Bank today announced the lineup for its Depositary Receipts ...
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will lead the business in the US and Canada, continuing to drive Ipsen’s positive impact...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today has pledged to play its part in securing global net-zero emissions, ahead of the COP26 conference in Glasgow, UK, next month. Ipsen is proud to have joined the Business Ambition for 1.5°C 1 campaign and is committ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales summary (unaudited IFRS consolidated sales) Highlights – Total ...
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen’s expansion into hematological malignancies, with a ...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005020/en/ Mari Scheiffele (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Mari Scheiffele ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...